A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

Prostate Cancer Clinical Trial

Official title:

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03311555
• Other study ID #: Pro00080868
• Status: Completed
• Phase: Phase 2
• Start date: March 28, 2018
• Est. completion date: December 22, 2022

Study information

• Verified date: February 2024
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to describe the rate of 3-year progression free survival in men with recurrent PSA-only disease after prostatectomy, who receive combined apalutamide (ARN-509) and standard ADT with salvage radiation therapy followed by docetaxel, ADT, and apalutamide, AND who have had testosterone recovery to >100 ng/dl at 36 months. The hypothesis is that AR inhibition with apalutamide added to standard salvage external beam radiation with androgen deprivation therapy, as well as the addition of 6 cycles of docetaxel, will further prolong progression free survival.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: December 22, 2022
• Est. primary completion date: December 22, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically-confirmed diagnosis of prostate adenocarcinoma. Variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate, are not permitted.

2. Gleason sum of 7 (with pT3 disease or positive margins or positive nodes [4 or fewer]), 8, 9, or 10 based on the radical prostatectomy specimen

3. PSA relapse within 4 years of prostatectomy defined by persistently detectable or rising PSA after surgery.

4. Evidence of disease recurrence or progression as evidenced by a PSA > 0.20. This requires 2 consecutive rises in PSA, at least 1 week apart, over the post-prostatectomy nadir OR one PSA value above 0.20 ng/mL IF the patient failed to achieve a post-prostatectomy nadir of < 0.2 ng/mL.

5. Age = 18 years

6. Karnofsky performance status = 80

7. Adequate laboratory parameters

• Adequate bone marrow function: ANC =1.5 x 109/L, Platelets =100 x 109/L, Hb >9g/dL
• AST/SGOT and ALT/SGPT = 2.5 x Institutional Upper Limit of Normal (ULN)
• Serum bilirubin = 1.5 x Institutional ULN (In subjects with Gilbert's syndrome, if total bilirubin is > 1.5xULN, measure direct and indirect bilirubin and patient is eligible if direct bilirubin = 1.5xULN).
• Glomerular filtration rate (either estimated or calculated from 24-hour urine collection) = 45 mL/min
• Serum potassium =3.5 mmol/L

8. A minimum of 4 weeks from any major surgery prior to Cycle 1 Day 1.

9. Ability to swallow, retain, and absorb oral medication.

10. Ability to understand and the willingness to sign a written informed consent document.

11. Must use a condom if having sex with a pregnant woman.

12. Male patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration.

Exclusion Criteria:

1. Radiographic evidence of metastatic disease. Patients with node-positive disease (=4 positive nodes) at the time of radical prostatectomy are eligible. Patients with pelvic nodes less than 1.5 cm by short axis at the time of screening are eligible. Patients with any enlarged lymph nodes in the retroperitoneum or above the aortic bifurcation or with pelvic nodes = 1.5 cm must be excluded.

2. PSA = 4.0 ng/mL.

3. Testosterone level = 100 ng/dL.

4. More than 1 month of prior hormone exposure or hormone exposure within 30 days of enrollment (up to 1 month of prior LHRH agonist and/or anti-androgen therapy as neoadjuvant therapy prior to prostatectomy is allowed). Prior enzalutamide, apalutamide, ketoconazole, abiraterone, or TAK700 for prostate cancer are prohibited. Prior antiandrogen therapy (including but not limited to bicalutamide, flutamide, nilutamide, enzalutamide, and apalutamide) and prior estrogen therapy (including estrogen patch) are not allowed. All investigational agents are prohibited within 30 days of enrollment.

5. The following medications are prohibited within 2 weeks of enrollment and while on

study drug:

• 5 a-reductase inhibitors (finasteride, dutasteride);
• Biologic or other agents with anti-tumor activity against prostate cancer;
• Systemic glucocorticoids greater than the equivalent of 10 mg per day of prednisone; oPremedication with systemic glucocorticoids greater than the equivalent of 10 mg per day of prednisone is permitted prior to docetaxel infusions.
• Androgens (testosterone, dihydroepiandrosterone [DHEA], etc.)

6. Prior immunotherapy including sipuleucel-T.

7. Prior systemic chemotherapy (docetaxel, cabazitaxel, estramustine, other cytotoxic agents)

8. History of solid organ or stem cell transplantation.

9. History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, prior head or traumatic brain injury with loss of consciousness, prior or current space-occupying lesion in the brain). Also, history of loss of consciousness or transient ischemic attack within 12 months of Day 1 visit.

10. Known or suspected brain metastasis or active leptomeningeal disease.

11. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.

12. Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to enrollment

13. Sustained uncontrolled hypertension (>150/90 average over 1 week) despite optimal medical management

14. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of apalutamide or increase the risk of radiation (e.g., uncontrolled nausea, vomiting, diarrhea, malabsorption syndromes, prior small bowel resection, or inflammatory bowel disease).

15. Patients who have received prior prostate or pelvic radiotherapy, including external beam or brachytherapy.

16. Patients who have not recovered from side effects of prior systemic therapy prior to Cycle 1 Day 1.

17. Use of medications known to lower the seizure threshold within 4 weeks prior to study entry.

18. Patients unable or unwilling to abide by the study protocol or cooperate fully with the investigator.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Apalutamide
240mg tablet daily for 36 weeks
• Androgen deprivation
ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.

Radiation:
• Salvage radiation therapy
On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks

Drug:
• Docetaxel
About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.

Locations

Country	Name	City	State
United States	Duke Cancer Center Cary	Cary	North Carolina
United States	Duke University Medical Center	Durham	North Carolina
United States	Weill Cornell Medical Center	New York	New York
United States	GU Research Network / Urology Cancer Center	Omaha	Nebraska
United States	Wake Forest Univesity	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Andrew J. Armstrong, MD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free Survival (PFS) at 36 Months (3 Years)	The percentage of subjects with testosterone >100 ng/dl at 36 months post-Cycle 1 Day 1 without one or more of the following: Serum PSA value of 0.2 ng/mL or more above the post-radiotherapy PSA nadir and confirmed (at least) 4 weeks later by a second PSA measurement higher than the first by any amount; Continued rise in the PSA level following study treatment if no nadir is experienced, defined as 2 rising values greater than the baseline PSA and separated by at least 4 weeks; Evidence of clinical progression or initiation of systemic therapy for progressive disease; Death	up to 36 months
Secondary	Number of Participants With a PSA of <0.1 ng/mL and Testosterone Recovery at 12 Months Post-Cycle 1 Day 1	Testosterone recovery defined as testosterone >100 ng/dl	12 months
Secondary	Percentage of Participants With a PSA of <0.1 ng/mL and Testosterone Recovery at 24 Months Post-Cycle 1 Day 1	Testosterone recovery defined as testosterone >100 ng/dl	24 months
Secondary	Percentage of Participants With a PSA of <0.1 ng/mL and Testosterone Recovery at 36 Months Post-Cycle 1 Day 1	Testosterone recovery defined as testosterone >100 ng/dl	36 months
Secondary	Biochemical Progression-free Survival (PFS) at 36 Months (3 Years)	Percentage of participants still alive without disease progression based on PSA (prostate-specific antigen) only. Must have serum PSA value of 0.2 ng/mL or more above the post-radiotherapy PSA nadir and confirmed (at least) 4 weeks later by a second PSA measurement higher than the first by any amount.	36 months
Secondary	Median PSA Nadir Value	Median PSA nadir value	36 months
Secondary	Time to Testosterone Recovery	Testosterone recovery defined as testosterone >100 ng/dl	up to 36 months
Secondary	Percentage of Participants With Adverse Events as Assessed by CTCAE v4.0	To describe the safety, feasibility and tolerability profile of combination apalutamide, ADT, and radiation therapy followed by apalutamide, ADT, and docetaxel as assessed by NCI common toxicity scales	up to 36 months
Secondary	Percentage of Participants Completing All Treatments	To describe the percentage of participants completing all treatments including salvage radiation therapy and 6 cycles of docetaxel	36 months